Dydrogesterone 10mg tablets (Nalvee®) added to the HRT PPC medicines list

From 1 September 2025,  Dydrogesterone 10mg tablets (Nalvee^®) has been added to the list of medicines covered by the HRT prepayment certificate (HRT PPC).

This change has been reflected in Part XVI of the September 2025 Drug Tariff and on the NHSBSA’s website. Community Pharmacy England has also updated its HRT medicines list to reflect the changes taking effect from September 2025. Please note: you may need to hard refresh (press Ctrl+R) to refer to the most up-to-date version.

Other changes to Part XVI of the September 2025 Drug Tariff: Pfizer Limited recently ceased supplying Premarin^® and Premique^® Low Dose and has released generic equivalent versions instead. These generic versions are covered by the HRT PPC. For more information, see Drug Tariff Watch – September 2025.

The HRT medicines list has been compiled following consultation with the Medicines and Healthcare products Regulatory Agency (MHRA), NHSBSA and the NHS England Menopause Clinical Reference Group. The list will be updated as new HRT medicines licensed for the treatment of menopause become available in the UK or as existing HRT medicines are discontinued from the UK market. If a product that meets the criteria is missing from the HRT medicines list, please contact dhsc.publicenquiries@dhsc.gov.uk.

The NHS Business Services Authority (NHSBSA) has seen an increase in the number of prescriptions from patients using the “HRT only prescription prepayment certificate” prescription charge exemption category for products that are not covered by the HRT PPC. Pharmacy teams are encouraged to familiarise themselves with the full list of eligible HRT medicines to help patients avoid making incorrect exemption claims. Click here for further information.